WO2018148499A1 - Séquences peptidiques de flavivirus, épitopes, et procédés et utilisations de ceux-ci - Google Patents
Séquences peptidiques de flavivirus, épitopes, et procédés et utilisations de ceux-ci Download PDFInfo
- Publication number
- WO2018148499A1 WO2018148499A1 PCT/US2018/017554 US2018017554W WO2018148499A1 WO 2018148499 A1 WO2018148499 A1 WO 2018148499A1 US 2018017554 W US2018017554 W US 2018017554W WO 2018148499 A1 WO2018148499 A1 WO 2018148499A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- zikv
- mice
- cells
- denv
- cell
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 104
- 241000710831 Flavivirus Species 0.000 title claims abstract description 43
- 238000000034 method Methods 0.000 title claims abstract description 34
- 241000907316 Zika virus Species 0.000 claims abstract description 242
- 208000015181 infectious disease Diseases 0.000 claims abstract description 83
- 239000000203 mixture Substances 0.000 claims abstract description 23
- 241000725619 Dengue virus Species 0.000 claims abstract description 17
- 230000028993 immune response Effects 0.000 claims abstract description 10
- 230000002708 enhancing effect Effects 0.000 claims abstract description 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 107
- 230000005867 T cell response Effects 0.000 claims description 31
- 150000001413 amino acids Chemical class 0.000 claims description 28
- 230000004044 response Effects 0.000 claims description 28
- 239000002671 adjuvant Substances 0.000 claims description 11
- 239000000523 sample Substances 0.000 claims description 9
- 102100032912 CD44 antigen Human genes 0.000 claims description 5
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 5
- 238000000338 in vitro Methods 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000012545 processing Methods 0.000 claims description 3
- 230000004913 activation Effects 0.000 claims description 2
- 239000012472 biological sample Substances 0.000 claims 2
- 101001018097 Homo sapiens L-selectin Proteins 0.000 claims 1
- 102100033467 L-selectin Human genes 0.000 claims 1
- 241000767684 Thoe Species 0.000 claims 1
- 238000003018 immunoassay Methods 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 59
- 208000020329 Zika virus infectious disease Diseases 0.000 abstract description 52
- 230000001939 inductive effect Effects 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 178
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 80
- 210000004027 cell Anatomy 0.000 description 65
- 208000001455 Zika Virus Infection Diseases 0.000 description 44
- 241000700605 Viruses Species 0.000 description 43
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 24
- 208000025729 dengue disease Diseases 0.000 description 23
- 230000001605 fetal effect Effects 0.000 description 23
- 206010012310 Dengue fever Diseases 0.000 description 22
- 230000000670 limiting effect Effects 0.000 description 22
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
- 210000004556 brain Anatomy 0.000 description 21
- 210000000952 spleen Anatomy 0.000 description 21
- 108090000623 proteins and genes Proteins 0.000 description 20
- 230000008774 maternal effect Effects 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 235000001014 amino acid Nutrition 0.000 description 17
- 210000003754 fetus Anatomy 0.000 description 17
- 230000036039 immunity Effects 0.000 description 17
- 230000035935 pregnancy Effects 0.000 description 17
- 208000001490 Dengue Diseases 0.000 description 16
- 210000003785 decidua Anatomy 0.000 description 16
- 210000002826 placenta Anatomy 0.000 description 16
- 108020004707 nucleic acids Proteins 0.000 description 15
- 102000039446 nucleic acids Human genes 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 14
- 108010075704 HLA-A Antigens Proteins 0.000 description 14
- 238000003556 assay Methods 0.000 description 14
- 230000002458 infectious effect Effects 0.000 description 14
- 150000007523 nucleic acids Chemical class 0.000 description 14
- 102000004127 Cytokines Human genes 0.000 description 13
- 108090000695 Cytokines Proteins 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 229960005486 vaccine Drugs 0.000 description 13
- 238000011740 C57BL/6 mouse Methods 0.000 description 12
- 108010078301 HLA-B*07:02 antigen Proteins 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 210000004988 splenocyte Anatomy 0.000 description 12
- 230000003612 virological effect Effects 0.000 description 12
- 102210024302 HLA-B*0702 Human genes 0.000 description 11
- 241000699660 Mus musculus Species 0.000 description 11
- 101710144121 Non-structural protein 5 Proteins 0.000 description 11
- 239000002253 acid Substances 0.000 description 11
- 230000001681 protective effect Effects 0.000 description 11
- 238000011830 transgenic mouse model Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
- 108020004705 Codon Proteins 0.000 description 10
- 241000282412 Homo Species 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 238000010172 mouse model Methods 0.000 description 10
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 9
- 108010058607 HLA-B Antigens Proteins 0.000 description 9
- 108010050904 Interferons Proteins 0.000 description 9
- 102000014150 Interferons Human genes 0.000 description 9
- 240000005076 Livistona saribus Species 0.000 description 9
- 235000008297 Livistona saribus Nutrition 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 230000001404 mediated effect Effects 0.000 description 9
- 238000011510 Elispot assay Methods 0.000 description 8
- 102000001398 Granzyme Human genes 0.000 description 8
- 208000035332 Zika virus disease Diseases 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 229910003460 diamond Inorganic materials 0.000 description 8
- 239000010432 diamond Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 108060005986 Granzyme Proteins 0.000 description 7
- 101000852870 Homo sapiens Interferon alpha/beta receptor 1 Proteins 0.000 description 7
- 102100036714 Interferon alpha/beta receptor 1 Human genes 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 101710144111 Non-structural protein 3 Proteins 0.000 description 7
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 7
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 7
- 230000002950 deficient Effects 0.000 description 7
- 229940079322 interferon Drugs 0.000 description 7
- 208000004141 microcephaly Diseases 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- 206010010356 Congenital anomaly Diseases 0.000 description 6
- 101800001019 Non-structural protein 4B Proteins 0.000 description 6
- 238000011529 RT qPCR Methods 0.000 description 6
- 230000036755 cellular response Effects 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 150000002500 ions Chemical class 0.000 description 6
- 208000032170 Congenital Abnormalities Diseases 0.000 description 5
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 241000726306 Irus Species 0.000 description 4
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical group CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 4
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 description 4
- 208000009714 Severe Dengue Diseases 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 230000007969 cellular immunity Effects 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 210000003128 head Anatomy 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 210000000582 semen Anatomy 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 241000370685 Arge Species 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- 101100536354 Drosophila melanogaster tant gene Proteins 0.000 description 3
- 208000001362 Fetal Growth Retardation Diseases 0.000 description 3
- 208000009628 Fetal Resorption Diseases 0.000 description 3
- 206010070531 Foetal growth restriction Diseases 0.000 description 3
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 3
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 3
- 101150106931 IFNG gene Proteins 0.000 description 3
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 3
- 101800001030 Non-structural protein 2A Proteins 0.000 description 3
- 241000949477 Toona ciliata Species 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 3
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000007698 birth defect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- -1 but not limited to Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000009260 cross reactivity Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 206010014599 encephalitis Diseases 0.000 description 3
- 208000030941 fetal growth restriction Diseases 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- 230000037452 priming Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 238000004808 supercritical fluid chromatography Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241001428800 Cell fusing agent virus Species 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108010062580 Concanavalin A Proteins 0.000 description 2
- 241000255925 Diptera Species 0.000 description 2
- 206010054261 Flavivirus infection Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 241000282560 Macaca mulatta Species 0.000 description 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 2
- 101800001020 Non-structural protein 4A Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 206010058874 Viraemia Diseases 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- 241000710886 West Nile virus Species 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 108010007338 atrial natriuretic factor 88 Proteins 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 208000035850 clinical syndrome Diseases 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000001461 cytolytic effect Effects 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000004578 fetal growth Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- UKAUYVFTDYCKQA-UHFFFAOYSA-N homoserine Chemical compound OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 2
- 210000000066 myeloid cell Anatomy 0.000 description 2
- 239000007923 nasal drop Substances 0.000 description 2
- 229940100662 nasal drops Drugs 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- WTEVQBCEXWBHNA-YFHOEESVSA-N neral Chemical compound CC(C)=CCC\C(C)=C/C=O WTEVQBCEXWBHNA-YFHOEESVSA-N 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 230000003169 placental effect Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000005582 sexual transmission Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 230000009447 viral pathogenesis Effects 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- GXMBHQRROXQUJS-UHFFFAOYSA-N (2-hept-2-ynylsulfanylphenyl) acetate Chemical compound CCCCC#CCSC1=CC=CC=C1OC(C)=O GXMBHQRROXQUJS-UHFFFAOYSA-N 0.000 description 1
- BHMLFPOTZYRDKA-IRXDYDNUSA-N (2s)-2-[(s)-(2-iodophenoxy)-phenylmethyl]morpholine Chemical compound IC1=CC=CC=C1O[C@@H](C=1C=CC=CC=1)[C@H]1OCCNC1 BHMLFPOTZYRDKA-IRXDYDNUSA-N 0.000 description 1
- MJWYCUZCRGLCBD-BGZMIMFDSA-N (4s)-4-amino-5-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCC(O)=O MJWYCUZCRGLCBD-BGZMIMFDSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- LHASLBSEALHFGO-ASZAQJJISA-N 1-[(4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]pyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO)OC1N1C(=O)NC(=O)C(CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1 LHASLBSEALHFGO-ASZAQJJISA-N 0.000 description 1
- WYFYSTBFFDOVJW-UHFFFAOYSA-L 2-[4-[4-(3,5-diphenyltetrazol-2-ium-2-yl)phenyl]phenyl]-3,5-diphenyltetrazol-2-ium;dichloride Chemical compound [Cl-].[Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC(=CC=2)C=2C=CC(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC=CC=2)=NN1C1=CC=CC=C1 WYFYSTBFFDOVJW-UHFFFAOYSA-L 0.000 description 1
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 1
- JBCBWDYSSJINSH-UHFFFAOYSA-N 5-(butoxymethylsulfamoyl)-4-chloro-2-(furan-2-ylmethylamino)benzoic acid Chemical compound C1=C(Cl)C(S(=O)(=O)NCOCCCC)=CC(C(O)=O)=C1NCC1=CC=CO1 JBCBWDYSSJINSH-UHFFFAOYSA-N 0.000 description 1
- YGGTVPCTAKYCSQ-UHFFFAOYSA-N 6-methoxyquinolin-8-amine Chemical compound N1=CC=CC2=CC(OC)=CC(N)=C21 YGGTVPCTAKYCSQ-UHFFFAOYSA-N 0.000 description 1
- OXEUETBFKVCRNP-UHFFFAOYSA-N 9-ethyl-3-carbazolamine Chemical compound NC1=CC=C2N(CC)C3=CC=CC=C3C2=C1 OXEUETBFKVCRNP-UHFFFAOYSA-N 0.000 description 1
- 102100040190 ADP-ribosylation factor-binding protein GGA2 Human genes 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 241000065118 Aclella nova Species 0.000 description 1
- 241000256173 Aedes albopictus Species 0.000 description 1
- 241001136792 Alle Species 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000566146 Asio Species 0.000 description 1
- 206010071155 Autoimmune arthritis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 101100272279 Beauveria bassiana Beas gene Proteins 0.000 description 1
- 240000001546 Byrsonima crassifolia Species 0.000 description 1
- 235000003197 Byrsonima crassifolia Nutrition 0.000 description 1
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 108090000835 CX3C Chemokine Receptor 1 Proteins 0.000 description 1
- 102100039196 CX3C chemokine receptor 1 Human genes 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 101150087313 Cd8a gene Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241001301278 Cerion Species 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- RAPBNVDSDCTNRC-UHFFFAOYSA-N Chlorobenzilate Chemical compound C=1C=C(Cl)C=CC=1C(O)(C(=O)OCC)C1=CC=C(Cl)C=C1 RAPBNVDSDCTNRC-UHFFFAOYSA-N 0.000 description 1
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 241000766026 Coregonus nasus Species 0.000 description 1
- 241001274613 Corvus frugilegus Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000032163 Emerging Communicable disease Diseases 0.000 description 1
- 101710204837 Envelope small membrane protein Proteins 0.000 description 1
- 241000356151 Euphorbia decidua Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 239000004230 Fast Yellow AB Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000001951 Fetal Death Diseases 0.000 description 1
- 208000022471 Fetal disease Diseases 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- 241000190598 Flexal mammarenavirus Species 0.000 description 1
- 244000182067 Fraxinus ornus Species 0.000 description 1
- 102100027988 GTP-binding protein Rhes Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010061192 Haemorrhagic fever Diseases 0.000 description 1
- 101001037082 Homo sapiens ADP-ribosylation factor-binding protein GGA2 Proteins 0.000 description 1
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 1
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
- 101000578396 Homo sapiens GTP-binding protein Rhes Proteins 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 101800000324 Immunoglobulin A1 protease translocator Proteins 0.000 description 1
- 108010054267 Interferon Receptors Proteins 0.000 description 1
- 102000001617 Interferon Receptors Human genes 0.000 description 1
- 102000002227 Interferon Type I Human genes 0.000 description 1
- 108010014726 Interferon Type I Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 241001527806 Iti Species 0.000 description 1
- 241000710912 Kunjin virus Species 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical group OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-YGVKFDHGSA-N L-methionine (R)-S-oxide group Chemical group N[C@@H](CCS(=O)C)C(=O)O QEFRNWWLZKMPFJ-YGVKFDHGSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Natural products CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000272168 Laridae Species 0.000 description 1
- 101710145006 Lysis protein Proteins 0.000 description 1
- MVBPAIHFZZKRGD-UHFFFAOYSA-N MTIC Chemical compound CNN=NC=1NC=NC=1C(N)=O MVBPAIHFZZKRGD-UHFFFAOYSA-N 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000252067 Megalops atlanticus Species 0.000 description 1
- 241001164593 Merica Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000710908 Murray Valley encephalitis virus Species 0.000 description 1
- 101100170604 Mus musculus Dmap1 gene Proteins 0.000 description 1
- 101100233118 Mus musculus Insc gene Proteins 0.000 description 1
- 101100366940 Mus musculus Stom gene Proteins 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- SULCGGIVBSGPJA-UHFFFAOYSA-N NSSSS Chemical compound NSSSS SULCGGIVBSGPJA-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101100341230 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) isn-1 gene Proteins 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 208000036830 Normal foetus Diseases 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 101100261281 Oncorhynchus nerka trha gene Proteins 0.000 description 1
- 101150097800 PEBP1 gene Proteins 0.000 description 1
- 241000646189 Palm Creek virus Species 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 244000193463 Picea excelsa Species 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 241000350158 Prioria balsamifera Species 0.000 description 1
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 240000001987 Pyrus communis Species 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 101100290666 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ROX3 gene Proteins 0.000 description 1
- 241001591005 Siga Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 240000002825 Solanum vestissimum Species 0.000 description 1
- 235000018259 Solanum vestissimum Nutrition 0.000 description 1
- 239000004187 Spiramycin Substances 0.000 description 1
- FHNINJWBTRXEBC-UHFFFAOYSA-N Sudan III Chemical compound OC1=CC=C2C=CC=CC2=C1N=NC(C=C1)=CC=C1N=NC1=CC=CC=C1 FHNINJWBTRXEBC-UHFFFAOYSA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241000907517 Usutu virus Species 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 101150111878 Vegfd gene Proteins 0.000 description 1
- 101150118507 WASL gene Proteins 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- AYUNIORJHRXIBJ-HTLBVUBBSA-N [(3r,5s,6r,7s,8e,10s,11s,12e,14e)-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-21-(prop-2-enylamino)-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate Chemical compound N1C(=O)\C(C)=C\C=C\[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-HTLBVUBBSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- QXAITBQSYVNQDR-UHFFFAOYSA-N amitraz Chemical compound C=1C=C(C)C=C(C)C=1N=CN(C)C=NC1=CC=C(C)C=C1C QXAITBQSYVNQDR-UHFFFAOYSA-N 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000003441 anti-flavivirus Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 101150024767 arnT gene Proteins 0.000 description 1
- 101150014732 asnS gene Proteins 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000005821 brain abnormality Effects 0.000 description 1
- KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 1
- JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- WTEVQBCEXWBHNA-JXMROGBWSA-N citral A Natural products CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 210000002238 decidual nk cell Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 201000002950 dengue hemorrhagic fever Diseases 0.000 description 1
- 201000009892 dengue shock syndrome Diseases 0.000 description 1
- 229940023605 dengue virus vaccine Drugs 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 229950006137 dexfosfoserine Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000004193 disodium 5'-ribonucleotide Substances 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- MKHLSGKJYGBQLI-UHFFFAOYSA-N ethoxy-(2-ethylsulfanylethylsulfanyl)-methoxy-sulfanylidene-$l^{5}-phosphane Chemical compound CCOP(=S)(OC)SCCSCC MKHLSGKJYGBQLI-UHFFFAOYSA-N 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000009123 feedback regulation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 108700030379 flavivirus NS3 Proteins 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- UHBYWPGGCSDKFX-VKHMYHEASA-N gamma-carboxy-L-glutamic acid Chemical compound OC(=O)[C@@H](N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-VKHMYHEASA-N 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 239000010520 ghee Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 108010008118 glutamyl-leucyl-valyl-isoleucyl-serine Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000001985 kidney epithelial cell Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical group CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-O methylsulfide anion Chemical compound [SH2+]C LSDPWZHWYPCBBB-UHFFFAOYSA-O 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000001459 mortal effect Effects 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 208000037971 neglected tropical disease Diseases 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 230000005156 neurotropism Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 238000001558 permutation test Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Chemical compound OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 210000004909 pre-ejaculatory fluid Anatomy 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 210000003124 radial glial cell Anatomy 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- FESBVLZDDCQLFY-UHFFFAOYSA-N sete Chemical compound [Te]=[Se] FESBVLZDDCQLFY-UHFFFAOYSA-N 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000004402 sodium ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 210000001845 splenic macrophage Anatomy 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 239000004557 technical material Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 125000001493 tyrosinyl group Chemical class [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 230000005570 vertical transmission Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 239000000277 virosome Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
- CZPRKINNVBONSF-UHFFFAOYSA-M zinc;dioxido(oxo)phosphanium Chemical compound [Zn+2].[O-][P+]([O-])=O CZPRKINNVBONSF-UHFFFAOYSA-M 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/18—Togaviridae; Flaviviridae
- C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
- C07K14/1825—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/18—Togaviridae; Flaviviridae
- G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
- G01N2333/185—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- This genus includes the West (ZIKV) and several other viruses which may ca n u c s e e ph en al c i e ti p s h ( a T li B ti E s, ) virus, yellow fever virus, Zika virus (ISFs) such as cell fusing agent virus (CFAV), Palm Creek virus as (P wCeVll) a,s an indse Pcat-rsrapecific flaviviruses (PaRV).
- Flaviviruses are globally emerging flaviviruses are maintained in animal reservoirs fo inrm nat oufre en ancedp ahraelit tirsan or hemorrhagic fever. Most through the bite of an infected mosquito or tick. Other virus transsmmiisttseiodn to ro huutmesan csan pr iinmclaurdilye
- c leb e l s of ZIKA infection have no symptoms, but when present they are usually conju oer d joeningtu peai fne,v nera,u asenad, v moamyit cinaugs,e or fe lovsesr, o rfa asphp,e hteitaed.ache, pain behind the eyes, [ m00ic7r]ocepha Flyu hrtahser b,ee an c caounsafilrm reeldati ionn tshheip 20 b1e5tw
- Vaccines are currently available for only yellow fever and Japanese and TBE; however, heavwe v sahcociwnnes t fhoart d felanvgivuieru asneds, W esepstec Niaillley a dreen ingu celin viicrauls tr hiaalss in humans.
- many studies response during the infection (Diamo the ability to inhibit the innate immune 30; Jones M, Dav nd MS (September 2009), J.
- Interferon Cytokine Res.29 (9): 521– virus has many nidosonnst Aru,ct Huribable prtro Lt,ei ents al t.h (aMta ayllo 2w00 t5h)e. J i.nh Vibiriotli.o 7n9 o (f9) v:a 5ri4o1u4–20). Indeed, the dengue immune system response. Disease diagnosis can be dif s mediators of the innate genetically closely related ficult as all flaviviruses are antigenically and main approach to disease.
- o csom emprbisoidniged at l aenadst o bnroea isdolylate ddes pceripbteidde a hnedre ainn, ac thceept pabrelese cnatrri deirsc olros duilrueen rte,l tates to a
- p oeprt aidte le caostm 9p8r%is,in ogr a ant l aemasitn 9o9% ac,id or se 1q0u0e%nc iede wnhtiiccahl i tso at least 95%, or at least 96%, ohre a att l leeaasstt
- an amino acid sequence which is 95% identical w he isolated peptide may comprise NO: 1 and at least a second peptide i ith the amino acid sequence set forth in SEQ ID acid sequence which n the plurality of the isolated peptide may comprise an amino various possibilities o ifs h 9a8v%ing id deinfftiecraeln wti pthep tthidee a smeqinuoen acceid in se aqu pelunrcaelit syet o ffo prethpt iinde SsEQ ID NO: 2.
- the antigenic component may contain cells producing or rel xample, comprising an amino acid sequence which is at least 95 easing at least one peptide 98%, or at least 99%, or 100% identic %, or at least 96%, or at least 97%, or at least NO: 1 to SEQ ID NO: 93.
- h reu i eca r c hch a tpi is pe dpiftfiedreen otf t fhroem plu ornaleity an ooft thheer, is aosla dteedsc preibpetdide ab coomvepr wisitehs described methods, for example oenustic fo orr u psreev menatyat bivee t voac imcinpaletimonen atga ainnyst o an fela ovfiv tirhues.
- the m rises contacting the sample with the composition of the cell response, and detectin e g th t o h d e a p l r s e o se c n o c m e p o r r is a e b s s p e r n o c c e es o s f in t g he th T e c s e am ll p re le sp t o o n d se e .
- the method may further include causing a transmission of posed to the flavivirus.
- In expert may include a smartphone, a tablet, a ge ciated with the particular medical computing device and o tthheer e sluecitt neral purpose computer and/or any other suitable message and/or or any arbolneic ele ncotrtiofniciacti moness daagtea.
- the present disclosure further relates to a the methioodn o cfo tm r sustaining an immune response against a flavivirus in a subject, composit hepr pirseinsgent c doinstcaloctsiunrge.
- T cells of the subject with an effective amount of the [ a 0 m 01 o 7 u ] nt of th In e c o o n m e p n o o s n it - io lim n i t t o in t g he em su b b o je d c i t m .
- the contacting includes administrating the effective [ t0h0e18 e]ffective In am onoeun nto onf-li tmheitin cogm empobsoitdioimn,en ant,d th aedm coinntisatcrtaitning includes contacting T cells ex vivo with The method may further comprise expansion o g the contacted T cells to the subject. contacted T cells to the subject. f the T cells in vitro prior to administrating the 4
- i ats f,la tvhievir huesre inin a d seusbcrjeibcetd m mayet ahffoodrd of on ined tuoc oinbgt,ai ennh atan lecaisntg o,n oer i rnehdiubciet f tlhaveiv rus titer, increase or stimulate flavivirus clearance, reduce or a imruosu pnrto oliffe ara ftliaovni,v rireudsuc pero otrei innh oibri tth inec armeaoseusnt in flavivirus titer or flavivirus proliferation, inhibit synthesis of a flavivirus protein or a flavivirus nucleic of ac aid f.la .vivirus nucleic acid, or reduce or [ o0r02 su0]staining
- the flavivirus is a Zika virus.
- the flavivirus is a Dengue virus.
- composition of the present disclosure may include an acceptoabrele a ccacrerpietarb mleay ca brreie srel seecletecdted fro frmom go tlhde p aacrcteicpletasb,l sete crarriers described herein.
- acceptoabrele a ccacrerpietarb mleay ca brreie srel seecletecdted fro frmom go tlhde p aacrcteicpletasb,l sete crarriers described herein.
- buffered solutions buffered solutions.
- Carriers may inc ile water, saline, glucose, dextrose, or stabilizers (i lude auxiliary agents including, but not limited to, diluents, buffering age.en.t,s, s vuigsacrossit ayn ednh aamnicniong a acdiddsit)i,ve psr,e csoerlovrasti avnesd, th weet litkineg. agents, emulsifying agents, pH 5
- n v i san enc stlu , s mde uacy on h be aes ( aPoimfcmoe Lracbiaollryat aotownilsa,b Dleet arso,it f,o Mric ehx.a)m; Mpleer,ck Fr Aeudnjudv’san Itn 6c5om (Mpleertcek A anddjuvant and Cbolmep aledtjeuv Aandtjsuva anret irluminum salts such as aluminum hydroxide gel (alum) or alu Company, Inc., Rahway, N.J.); deorniv oatriz zeidnc p;o anlys inacscohluabrildee ssu;s ppoelnyspiohno of acylated tyrosine acylatmedin suumgar psh;o csapt
- TLR-4 S toulilt-albiklee mim type 4 (TLR-4) agonists (e.g., monophosphoryl lipid A (MPL), synthetic lipid A, lipid A CpGet oiclsigo osr, a lnipaloopgos)ly,s aalcucmhainriudme ( sLalPtsS,) cy otfok girnaems,-n saepgaotnivines, b macuterraima,yl p doilpypephtoidspeh (aMzeDnP) derivatives, virosomes, cochleates, poly(lactide-co-glycolides) (PLG) microparti es, emulsions, microparticles, liposomes, oil-in-water emulsions, MF59, a cles, poloxamer particles, adjuvants are not bacterial
- adjuvants which stimulate a Th1 type response sunch may include include certain synthetic polymers such as poly amino as 3DMPL or QS21. Adjuvants may also saponin, paraffin oil, and muramyl dipeptide. Adjuv acids and co-polymers of amino acids, immunomodulatory molecules encoded in a co- ants also encompass genetic adjuvants such as coinoculated DNA can be in the same plasmid inoculated DNA, or as CpG oligonucleotides. The DNA vector. The reader can refer to Vacc construct as the plasmid immunogen or in a separate of suitable adjuvant.
- compositions of the present disclosure may be formulated for parenteral nctteiodn i,n e u.gn.i,t d boysa bgoelu fsorm in,je ec.tgio.,n in o arm cpoonutliensu oorus in i mnfuulstiio-dno.se Fo cromntualianteions for an added preservative.
- the compositions may take such forms as suspension rs, with emulsions in oily or aqueous vehicles, and may contain formulatory a s, solutions or stabilizing and/or dispersing agenet,s e..
- composition of the present disclosure may be administered in the form suspensions may be foramtiuolna,te sduc ahcco asrd sitnegril teo i tnejcehcntaiqbulees aq kuneoowuns i onr th oelea agrtin uosuinsg su suspiteanbsleio dnis. These or wetting agents and suspending agents.
- the sterile injectable prepara spersing injectable solutions or suspensions in non-toxic parente tions may also be sterile may be given parenterally, for examp rally-acceptable diluents or solvents. They injection, by infusion o le intravenously, intramuscularly or sub-cutaneously by amount of each of the crom pepro onse.n Stusi itnab tlhee d coosmagpeossi wtioilnl, v tahrey, d deesipreednd eifnfgec utp (sohnor ftac otro lrosn sgu tcehrm as), t thhee
- the liquid antigen is freeze dried in the presence of agen xposure during drying.
- composition of the present disclosure may be formulated m cuti fdor (e r.egc.o anqsuteitouutsio fnor wmituhla wtioatne)r, o e.rg.
- o,t ahser sy sruuiptasb oler v suehspicelnes bioenfos,re or us me.ay Su bceh p lriqeuseidnted as a drug suay be prepared by conventional means with pharmaceutically acceptable ad preparations agespnetsnd (ein.gg., ag leecnitthsi (ne.g o.r, s aocrabciitao);l s nyornu-pa,q cueeloluuloss vee dheicrilvatives or hydrogenated edible fadtisti)v;e esmu sulscifhyin ags vegetable oils); and preservatives (e.gg., ag leecnitthsi (ne.g o.r, s aocrabciitao);l s n
- es e.g., almond oil, oily esters, or fractionated pharmaceutical compositi g., methyl or propyl-p-hydroxybenzoates or sorbic acid.
- the conventional means wions may take the form of, for example, tablets or capsules prepared by pregelatinized maize statrhch, ph paorlmyvainceyult picyarlrlyoli adcocneept oabrle hy edxrcoixpyiepnrotspy slu mcheth asylc beilnludloinsge); ag fiellnetrss ( (ee..gg.., lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g , stearate, talc or silica); disintegrants (e.g., potato starch or sodium star ., magnesium (e.g., sodium lauryl sulphate).
- the tablets may be coated by methods wcehll- gklyncoowlante i)n; o thre w aerttt.ing agents [ r0e0s3p5ir]atory ( We.gh.e nraesa tlh)e mu cocomspa,o tsyitpioicnally of it t ishe for pmreusleantet disclosure is intended for delivery to the an aerosol or nasal drops, or alternatively, d as an aqueous solution for administration as passage.
- Compositions for admi as a dry powder e.g.
- nasal drops may contain one or more excipients of the tonicity adjusting agents, su bcuhffe croinmgpo agsietniotsn,s, an fodr t ehxeam likpel.e V pirsecsoesrivtayti avgees,nt vsis ccaonsit bye ad mjuicsrtoincgrys atgaelnlintse, 8
- r eidon isn fo surc ahdm coinmisptroastiitoionn ass, d foryr trizeeha clohsaer,a acntedri xsytilcitso.l.
- Bulking and powder flow and size agents may app inrcolpurdieate m paonwnidtoerl, fl souwcro ansed, [ e0
- the herein described methods and/or kits may skide, a multi-well pla a membrane, a chip, a disk, a test strip, a filter, a microsphere, a usiellded wh iner t te, an optical fiber, and the like, or any other variant available to the person t eh ae s aarmtp wlieth toou bte d teepstaerdtin cgan fr boem ad tdheed p drerosepnwtis deis tcolo asu sarem.
- p Fleor ap epxalimcaptiloe,n a pa tedst pr setsriepnt m oany t bhe leest strip, and the presence of at least an isolated peptide compris
- p t is m idaednetic baals teod t
- su ide As discussed pepmtiudneo odfet tehceti polnur maleittyho odf t whheic ishol dateetdec ptsep ptriedseen ccoe of a plurality ofc thhe te issotl sattreipd m peapyti mdea,k weh uesree o efac anh different from one another, as describ mprises a respective amino acid sequence which is immunodetection method may include an imemd above with respect to the composition.
- Aodsi umseendt, he threein h,e threein ter dmesc“rpibacekdag kit may include at least one solid matrix or material such as glass, plastic, paper, fiber, f ed” can refer to the use of a fixed limits the at least one detection reagen oil and the like, capable of holding within include the at least one detecting ag t.
- the kit may milligram quantities of the at ent“packaged” in a glass vial used to contain microgram or may include the at least one detecting agent.
- the kit microgram quant least one detecting agent“packaged” in a microtiter plate well to which non-li ities of the at least one detecting agent has been operatively affixed.
- micropmairttinicgles e emnbtroadpipmeedn wt,ith thine a k pitor mouasy m inemclubdrae
- the kit may include the at least one detecting agent directly l , b t e es r t e s a t d r i i l p y o re r co d g ip n s i t z i e c d k, b e y tc t . h w os h e ic s h ki c ll o e n d ta in cts th t i h s e ar s t am wi p th le ou fl t ui d d e . p M ar a ti n n y g o fr t o h m er
- the herein described subject can be a mammal, preferably a human.
- Elements of one embodiment can be present invention wereill e bmebcoodmimee anptpsar wenittho tout th fuorsther mention.
- R 2 fl/ A fl m t o o use F m ig. ode 2 l C of s Z ho IK w V e in xe fe m ct p io la n ry in n a o c n c - o li r m da it n in ce g w r it e h su a lt n s obtained with a present disclosure; embodiment of the [ o 0 f 04 Z 3 I ] KV ep F i i t g o . p 3
- Fig.4A to Fig.4F show exemplary non-limiting results of polyfunctional phenotype of emKboVdim epeintotp oef- tshpeec pirfeicsen CtD di8s+clo Tsur cee;lls in LysMCre+IFNARfl/fl mice in accordance with an
- e nTt o d show graphs that illustrate non-limiting results of ZIKV burden in f am thse a pnredse tnhtei dris fceltoussuerse; on day 2 and 3 after ZIKV infection in [ e 0 p 0 i 5 to 7 p ] e-spe F ci i f g ic .1 C 8 D A 8 + to T F c i e g l .
- u m to Fig.22L show graphs that illustrate non-limiting results of the effect of a neb Iinfneadr1 C-/-D d4a + m asn idn C acDco8r + d Tan cceell w diethpl aentio enm obnod ZimIKenVt v oifra thle bu prrdeesenn itn d nisocnlo-ismurme;une [ f 0 ro 06 m 2] n Ton c-eilm Fi
- the flavivirus vaccine, diagnosis assay, and/or treatment approach [ r 0 e 0 la 6 t 8 e ] s to D I E n N o V n .
- the flavivirus vaccine, diagnosis assay, and/or treatment approach [ r 0 e 0 la 6 t 9 e ] s to ZI I K n V on a e nd em D b E o N di V m . ent, the flavivirus vaccine, diagnosis assay, and/or treatment approach
- ZIKV is a positive-sense, single-stranded, enveloped RNA flavivirus that was first m be i e lldat
- the virus i.e., serotypes
- serotypes the virus (i.e., serotypes)
- MHC I foreign peptides identifi bility complex class I
- nucleic acid is used sequences are displayed herein in the conventional 5’-3’e ooriteidneta,ti aonnd. polynucleotide.
- nucleotide [ r0e0fe8r3] to a po Tlyhmee trer omfs am“pinooly apceipdt rideesi,d”u“eps.ep Tthidee t”er and“protein” are used interchangeably herein to m as o w re el a l m as ino to ac n i a d tu r r e a s l i l d y u o e c i c s u a r n ri analog or mimetic omfs a a cpoprrlyes tpoo anmdiinngo n aactidur palolylylyly omcecrusrr ining wh amichin oon aeci odr, addition of carbohy ng amino acid polymers.
- Polypeptides can be modified, e.g., by the “protein” include gdlyractoepr roesteidinuse,s a tos f woermll a gslyc noopnr-ogtleyicnosp.r Tohteein tse.rm Tshe“p poolylpypepeptitdide,e” s“epqeupetnidcee”s and displayed herein in the conventional N-terminal to C-terminal orientation.
- Naturally occurring amino acids are those encoded by naturally well as those amino acids that are later modified, e.g., hydroxypr the genetic code, as phosphoserine.
- amino acid analogs oline, carboxyglutamate, and O- chemical structure as a naturally occurri refers to compounds that have the same basic hydrogen, a carboxyl group, an a ng amino acid, i.e., an .alpha. carbon that is bound to a methionine sulfoxide, meth mino group, and an R group, e.g., homoserine, norleucine, (e.g., norleucine) ionine, and methyl sulfonium.
- R group e.g., homoserine, norleucine, (e.g., norleucine) ionine, and methyl sulfonium.
- Such analogs have modified R groups naturally occurrin ogr a mmoindoifie adcid p.ep Atmidein boac ackibdon meism, betuicts re rteafienrs th teo s cahmeem bicaaslic co cmhepmoiucnalds str tuhcattu hreav aes a a
- nucleic acid does not encode an amino aci dentical amino acid sequences, or where Specifically, degenerate codon d sequence, to essentially identical sequences.
- t dheiordxyi pnoossiitnioen re o substitutions may be achieved by generating sequences in which the sifdu oense (B oartz mero erte a sl.e,l Necutecdleic (o Arc aidll) R ceos.d 1o9n:s50 i8s1 s (u1b9s9t1it)u;t Oedht wsuitkha e mti axle.,d J-base and/or 260:2605-2608 (1985); Rossolini et al., Mol. Cell. Probes 8:91-98 (1 . Biol. Chem.
- the codons GCA GC identical nucleic acids encode any given protein. every position where an alan C, GCG and GCU all encode the amino acid alanine.
- the codon can be S vaurcih he corresponding codons described without altering the encoded polypeptide.
- a polymerase e.g., a DNA polymerase.
- ences may be depicted in the form of a sequence listing, [ r0
- n e d xp tr r a e n ss s i l on refers to the transcription of a gene to produce the (i.e., a peptide, polypeptide, or proatteioinn).
- the te strain are alleviated or completely disease or s rm“preventing” refers to a process by which an infection or a delayed. ymptoms of an infection or a disease associated with a flavivirus are obstructed or [ c 0 o 0 m 95 p ] ound t T ha h t e ca e n xp b r e e a ss d i m on ini “ st a e n red ac t c o ep a t s a u b b le jec c t a w rr i i t e h r o ut m si a g y nif r i e c f a e n r t a to dve a rse ve e h f i f c
- adjuvants are believ w an adjuvant (humoral and/or cellular response) by ed to enhance the immune response strongly immunogenic in their own right an sldow arlye b reellieeavseindg to th fuenc atniotinge sny,ne wrghiisletica oltlhy.er adjuvants are
- Generally plate are coated with captu the membrane surfaces in a 96-well PVDF-membrane microtiter D se u ed ri e n d g i t n h t e o c t e h l e l i re antibody that binds a specific epitope of the cytokine being assayed.
- cytokine As d in the specific cells are activated, they release the cytokine, which is captured the antigen- surface by the immobilized antibody.
- the cytokine is thus“cap directly on the membrane surrounding the secreting cell, before it has a chance to diff tured” in the area directly degraded by proteases and bound by receptors on bystanuse into the culture media, or to be v acistuivaalitzeed t cheell.
- immobilized cytokine as an ImmunoSpot; essednetrial cleylls th.e Su sbecsreeqtuoernyt fo doettepcrtiniotn of ste thpes
- T ohfe m seea tseurrmemse innct,lu adned b inoctlhud qeua dnettietramtivinein agnd if/ aonr e qlueamlietanttiv is determinations, which both require sample processing and transformation steps of th e sample. Assessing may be relative or absolute.
- tr r e o a m tm o e te nt o . r F s o t r im e u x l a a m te p a le n , ti- th fl e avi i v m ir m us un a e cti s v y i s t t y em of c im ell m s u m ne ay sy in st c e l m ude ce T lls c i e n lls a , [ a0ll0o1w01 t]he co Tmhpeo enxepnrtes osrio cnom“tphoersapeutically effective amount” may include the amount necessary to ca ition to which it refers to perform its immunological role without T
- i t u hich the component or composition is administered.
- i osned be oirng th tere caotemdp, tohseiti toynpe to an bde a agdem ofin tihstered will vary treated, the mode of administration, as well as the other ingredients in the compositione. subject to be EXAMPLES
- Example 1 refers to the results shown in Fig.1A to Fig.8.
- Example 1 can be summarized as follows:
- [ f0o0r10 E7m]ergin ZgIK ViVru sstersai annsd M ARr7b66 and FSS13025 were obtained from the World Reference Center sentinel monkey rhesus (766) ino evaisruts Aesfri (cWaR (DCiEckV,A 19).52 M).R S7in66c,e A thfirsic iasonla ltinioena,ge th wea MsR is7o6l6ate isdol fartoem ha a b s weaesn is poalsastaegde idn o 2v0e1r01 f0r0om tim aes C ianm mboicdeia unsin pged iniattrraicce craesbera (lH ineaoncgul eattio alns (Dick, 1952).
- ZIKV FSS13025 low number of times.
- MR766 and FSS13025 were cultur ., 2012) and has been passaged a cells as described previously (Prestwoo ed using C6/36 Aedes albopictus mosquito 10 days after infect d et al., 2008).
- Virus was harvested from cell supernatants 7- ultrac ion, followed by clarification via centrifugation, and concentration via hamsteenrtr kiifdungeaytio (BnH aKs) p-r2e1vi coeulls-lbya dseedsc froibceuds-f (oPrrmesitnwgo aosdsa eyt ( aFlF.,A 2)0.1 Z2aI).
- mice were purchased from the Jackson laboratories, and LysMCre+IFNARfl/fl n -/- U C n 5 iv 7 e B r L si / ty 6 Sc m h i o ce ol o w f er M e ed b i r c e i d ne a A t n L im a al Jo F l a la cil I it n ie s s ti .
- n s th w is ith stu 20 d 0 y ⁇ an l d of a Z ll I i K n V viv i o n i 1 n 0 fe % ct F io B n S s / w P e B r S e r weu
- CMC carboxymethyl cellulose
- h ee 66 and FSS13025 was selected to identify s riz peedp.tides that overlapped by 11 amino acids 1.4 Peptide synthesis
- a CD t8+ T cells were isolated by magnetic bead positive selection (Miltenyi Biotec, p (I r m es m en o t b in il g on cTeMll - sot
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- General Physics & Mathematics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne une composition de matière, des procédés et l'utilisation de la composition de matière en rapport avec des peptides et épitopes de flavivirus, par exemple à des fins de vaccination thérapeutique ou préventive contre un flavivirus, et/ou pour induire, améliorer ou entretenir une réponse immunitaire contre un flavivirus, et/ou pour détecter une infection par un flavivirus ou une exposition à un flavivirus chez un sujet. Le flavivirus peut être, par exemple, le virus Zika et/ou le virus de la dengue.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/537,447 US11806393B2 (en) | 2017-02-10 | 2019-08-09 | Flavivirus peptide sequences, epitopes, and methods and uses thereof |
US18/368,949 US20240156939A1 (en) | 2017-02-10 | 2023-09-15 | Flavivirus peptide sequences, epitopes, and methods and uses thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762457753P | 2017-02-10 | 2017-02-10 | |
US62/457,753 | 2017-02-10 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/537,447 Continuation-In-Part US11806393B2 (en) | 2017-02-10 | 2019-08-09 | Flavivirus peptide sequences, epitopes, and methods and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018148499A1 true WO2018148499A1 (fr) | 2018-08-16 |
Family
ID=63107051
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2018/017554 WO2018148499A1 (fr) | 2017-02-10 | 2018-02-09 | Séquences peptidiques de flavivirus, épitopes, et procédés et utilisations de ceux-ci |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2018148499A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021127017A1 (fr) * | 2019-12-16 | 2021-06-24 | La Jolla Institute For Immunology | Combinaisons de protéines de flavivirus, séquences peptidiques, épitopes et procédés et utilisations de ceux-ci |
WO2021178281A1 (fr) * | 2020-03-03 | 2021-09-10 | Mayo Foundation For Medical Education And Research | Polypeptides du virus zika |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090221005A1 (en) * | 2006-03-20 | 2009-09-03 | St Vincent's Hospital Sydney Limited | Method for detecting antigen specific or mitogen-activated t cells |
WO2011163628A2 (fr) * | 2010-06-24 | 2011-12-29 | La Jolla Institute For Allergy And Immunology | Séquences polypeptidiques du virus de la dengue (dv), épitopes de lymphocytes t et leurs procédés et leurs utilisations |
EP2853590A1 (fr) * | 2012-05-22 | 2015-04-01 | The University of Tokyo | Procédé de production de lymphocytes t spécifiques d'un antigène |
-
2018
- 2018-02-09 WO PCT/US2018/017554 patent/WO2018148499A1/fr active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090221005A1 (en) * | 2006-03-20 | 2009-09-03 | St Vincent's Hospital Sydney Limited | Method for detecting antigen specific or mitogen-activated t cells |
WO2011163628A2 (fr) * | 2010-06-24 | 2011-12-29 | La Jolla Institute For Allergy And Immunology | Séquences polypeptidiques du virus de la dengue (dv), épitopes de lymphocytes t et leurs procédés et leurs utilisations |
EP2853590A1 (fr) * | 2012-05-22 | 2015-04-01 | The University of Tokyo | Procédé de production de lymphocytes t spécifiques d'un antigène |
Non-Patent Citations (5)
Title |
---|
BADAWI M. M. ET AL.: "Highly Conserved Epitopes of ZIKA Envelope Glycoprotein May Act as a Novel Peptide Vaccine with High Coverage: Immunoinformatics Approach", AMERICAN JOURNAL OF BIOMEDICAL RESEARCH, vol. 4, no. 3, 2016, pages 46 - 60, XP055537252 * |
JANAHI E. M. ET AL.: "In silico CD 4+, CD 8+ T- cell and B- CELL immunity associated immunogenic epitope prediction and HLA distribution analysis of Zika virus", EXCLI JOURNAL, vol. 16, 13 January 2017 (2017-01-13), pages 63 - 72, XP055537261 * |
MIRZA M. U. ET AL.: "Towards peptide vaccines against Zika virus: Immunoinformatics combined with molecular dynamics simulations to predict antigenic epitopes of Zika viral proteins", SCIENTIFIC REPORTS, vol. 6, no. 37313, 9 December 2016 (2016-12-09), pages 1 - 17, XP055537239 * |
NGONO A. E. ET AL.: "Mapping and Role of the CD 8+ T Cell Response During Primary Zika Virus Infection in Mice", CELL HOST & MICROBE, vol. 21, no. 1, 11 January 2017 (2017-01-11), pages 35 - 46, XP029881010 * |
SARMA K. ET AL.: "Immunoinformatics screening of prospective MHC class I restricted cytotoxic T- cell based epitopes in Zika virus", INTERNATIONAL JOURNAL OF CURRENT ADVANCED RESEARCH, vol. 5, no. 9, September 2016 (2016-09-01), pages 1229 - 1235, XP055537245 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021127017A1 (fr) * | 2019-12-16 | 2021-06-24 | La Jolla Institute For Immunology | Combinaisons de protéines de flavivirus, séquences peptidiques, épitopes et procédés et utilisations de ceux-ci |
WO2021178281A1 (fr) * | 2020-03-03 | 2021-09-10 | Mayo Foundation For Medical Education And Research | Polypeptides du virus zika |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Petitdemange et al. | Vaccine induction of antibodies and tissue-resident CD8+ T cells enhances protection against mucosal SHIV-infection in young macaques | |
von Herrath et al. | CD4-deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge | |
JP2020073527A (ja) | プログラム細胞死1(pd−1)経路を阻害することによる持続感染および癌の処置のための方法および組成物 | |
RU2682726C9 (ru) | Вакцинная композиция против злокачественной опухоли | |
Kang et al. | Lymphocytic choriomeningitis infection of the central nervous system | |
Wang et al. | Novel exosome-targeted T-cell-based vaccine counteracts T-cell anergy and converts CTL exhaustion in chronic infection via CD40L signaling through the mTORC1 pathway | |
WO2021076010A1 (fr) | Agent pharmaceutique pour induire une immunité spécifique contre le sras-cov-2 | |
US10144766B2 (en) | Cytotoxic T Lymphocyte inducing immunogens for prevention treatment and diagnosis of dengue virus infection | |
CN101557823A (zh) | 人内源性逆转录病毒多肽组合物和其使用方法 | |
JP2018524335A (ja) | Hiv予備免疫化および免疫療法 | |
US11660335B2 (en) | Vaccines against coronavirus and methods of use | |
Kaw et al. | HIV‐1 infection of CD4 T cells impairs antigen‐specific B cell function | |
EP2548567A1 (fr) | Peptides du virus JC du polyome et protéines pour application de vaccination et de diagnostic | |
WO2016178811A1 (fr) | Glycoproteine hemagluttinine h7 modifiee de la sequence h7 a/shanghai/2/2013 h7 de la grippe | |
WO2018148499A1 (fr) | Séquences peptidiques de flavivirus, épitopes, et procédés et utilisations de ceux-ci | |
US10052377B2 (en) | Cellular vaccine and method of inducing an immune response in a subject | |
Perdiguero et al. | Immunogenicity and efficacy of a novel multi-patch SARS-CoV-2/COVID-19 vaccine candidate | |
CN101370517B (zh) | 来源于c型肝炎病毒的肽 | |
Song et al. | A synthetic SARS-CoV-2-derived T-cell and B-cell peptide cocktail elicits full protection against lethal Omicron BA. 1 infection in H11-K18-hACE2 mice | |
Takagi et al. | Highly efficient antiviral CD8+ T-cell induction by peptides coupled to the surfaces of liposomes | |
Sundaram et al. | Protective Efficacy of Multiepitope Human Leukocyte Antigen–A* 0201 Restricted Cytotoxic T-Lymphocyte Peptide Construct Against Challenge With Human T-Cell Lymphotropic Virus Type 1 Tax Recombinant Vaccinia Virus | |
US20070160571A1 (en) | Composition and method for inducing protective vaccine response | |
WO2011048766A1 (fr) | Anhydrase carbonique i servant de nouvel antigène à utiliser pour le traitement de maladies autoimmunes | |
US20240156939A1 (en) | Flavivirus peptide sequences, epitopes, and methods and uses thereof | |
US20240041994A1 (en) | Cmv vaccine and method of making and using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18751677 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18751677 Country of ref document: EP Kind code of ref document: A1 |